• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酒精摄入导致的慢性前列腺炎/慢性盆腔疼痛综合征加重与肠道微生物群驱动的短链脂肪酸丙酸酯和丁酸酯减少有关。

Alcohol Intake-Induced Aggravation of Chronic Prostatitis/Chronic Pelvic Pain Syndrome is Associated with Reduced Gut Microbiota-Driven Short-Chain Fatty Acid Propionate and Butyrate.

作者信息

Liu Chang, Yue Shaoyu, Niu Di, Zhang Ligang, Chen Jing, Chen Yang, Guan Yu, Hua Xiaoliang, Chen Xianguo, Zhang Li, Du Hexi, Liang Chaozhao

机构信息

Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China.

Institute of Urology, Anhui Medical University, Hefei, China.

出版信息

World J Mens Health. 2025 Jun 2. doi: 10.5534/wjmh.240223.

DOI:10.5534/wjmh.240223
PMID:40583013
Abstract

PURPOSE

Chronic prostatitis (CP) is a common urological disease and about 8.4% to 13.5% of men suffer from prostatitis symptoms in China. This study was conducted to evaluate the effect of alcohol usage on patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and the role of the gut microbiome in this course.

MATERIALS AND METHODS

A total of 151 individuals were recruited when they were diagnosed with CP/CPPS. Eventually, 38 patients were enrolled and grouped into three groups: the CP/CPPS group, alcohol group, and quitter group. 16S ribosomal ribonucleic acid sequencing was used to investigate the fecal samples, and a liquid chromatograph-mass spectrometer was used to analyze untargeted metabolomics. Next, targeted identification of short-chain fatty acids was carried out. T helper 17 (Th17) cells and cytokines were measured by flow cytometry and enzyme-linked immunosorbent assay, respectively. Furthermore, the associations among intestinal microbiota, short-chain fatty acids, and clinical symptoms were evaluated through correlation analysis.

RESULTS

Alcohol consumption results in different microbial composition in patients with CP. Higher symptom scores, Th17 cell percentages and interleukin-17 concentrations were observed in the alcohol group. Notably, correlation analysis revealed that several gut microbes were correlated with propionate and butyrate contents and patient's symptoms. Contrarily, lower symptom scores, Th17 cell percentages and interleukin-17 concentrations were observed in the quitter group.

CONCLUSIONS

This study preliminarily explores the potential association between alcohol and CP/CPPS, in which short-chain fatty acid-producing gut flora may play a key role. This study may enhance the understanding of the effect of alcohol on CP/CPPS and provide a preliminary foundation for formulating prevention strategies. The main limitation of this study is the small sample size, and further large-scale plus in-depth research ought to be carried out in the future.

摘要

目的

慢性前列腺炎(CP)是一种常见的泌尿系统疾病,在中国约有8.4%至13.5%的男性患有前列腺炎症状。本研究旨在评估饮酒对慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)患者的影响以及肠道微生物群在这一过程中的作用。

材料与方法

共有151名被诊断为CP/CPPS的个体被招募。最终,38名患者被纳入并分为三组:CP/CPPS组、饮酒组和戒酒组。采用16S核糖体核糖核酸测序研究粪便样本,并使用液相色谱 - 质谱仪分析非靶向代谢组学。接下来,进行短链脂肪酸的靶向鉴定。分别通过流式细胞术和酶联免疫吸附测定法测量辅助性T细胞17(Th17)细胞和细胞因子。此外,通过相关性分析评估肠道微生物群、短链脂肪酸和临床症状之间的关联。

结果

饮酒导致CP患者的微生物组成不同。饮酒组观察到更高的症状评分、Th17细胞百分比和白细胞介素 - 17浓度。值得注意的是,相关性分析显示几种肠道微生物与丙酸和丁酸含量以及患者症状相关。相反,戒酒组观察到较低的症状评分、Th17细胞百分比和白细胞介素 - 17浓度。

结论

本研究初步探讨了酒精与CP/CPPS之间的潜在关联,其中产生短链脂肪酸的肠道菌群可能起关键作用。本研究可能增强对酒精对CP/CPPS影响的理解,并为制定预防策略提供初步基础。本研究的主要局限性是样本量小,未来应进行进一步的大规模深入研究。

相似文献

1
Alcohol Intake-Induced Aggravation of Chronic Prostatitis/Chronic Pelvic Pain Syndrome is Associated with Reduced Gut Microbiota-Driven Short-Chain Fatty Acid Propionate and Butyrate.酒精摄入导致的慢性前列腺炎/慢性盆腔疼痛综合征加重与肠道微生物群驱动的短链脂肪酸丙酸酯和丁酸酯减少有关。
World J Mens Health. 2025 Jun 2. doi: 10.5534/wjmh.240223.
2
Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.治疗慢性前列腺炎/慢性盆腔疼痛综合征的非药物干预措施。
Cochrane Database Syst Rev. 2018 May 12;5(5):CD012551. doi: 10.1002/14651858.CD012551.pub3.
3
Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.治疗慢性前列腺炎/慢性盆腔疼痛综合征的非药物干预措施。
Cochrane Database Syst Rev. 2018 Jan 26;1(1):CD012551. doi: 10.1002/14651858.CD012551.pub2.
4
Pregabalin for chronic prostatitis.普瑞巴林用于治疗慢性前列腺炎。
Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD009063. doi: 10.1002/14651858.CD009063.pub2.
5
Comparative analysis of efficacy of different combination therapies of α-receptor blockers and traditional Chinese medicine external therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: Bayesian network meta-analysis.比较α受体阻滞剂与中药外治不同联合方案治疗慢性前列腺炎/慢性盆腔疼痛综合征疗效的系统评价:贝叶斯网状 Meta 分析。
PLoS One. 2023 Apr 20;18(4):e0280821. doi: 10.1371/journal.pone.0280821. eCollection 2023.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Abnormal Gut Microbiota is Associated with Depressive-like Behavior in the Rat Model of Autoimmune Prostatitis.异常肠道微生物群与自身免疫性前列腺炎大鼠模型中的抑郁样行为有关。
Appl Biochem Biotechnol. 2025 Jun 27. doi: 10.1007/s12010-025-05294-1.
9
Acupuncture for Chronic Prostatitis or Chronic Pelvic Pain Syndrome: An Updated Systematic Review and Meta-Analysis.针刺治疗慢性前列腺炎/慢性骨盆疼痛综合征的疗效:一项更新的系统评价和荟萃分析。
Pain Res Manag. 2023 Mar 14;2023:7754876. doi: 10.1155/2023/7754876. eCollection 2023.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.